The chemotherapy regimens recommended in the 6th edition of the Japanese guidelines for the treatment of gastric cancer, which was revised in July 2021 [9], are described differently for HER2-positive and HER2-negative cases. The gene discussed is ERBB2; the disease is gastric cancer.